IRADIMED CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.86 USD | +0.94% |
|
+2.10% | -11.82% |
| Apr. 03 | IRadimed Files $75 Million Common Stock Shelf Registration | MT |
| Feb. 08 | Transcript : IRadimed Corporation, Q4 2023 Earnings Call, Feb 08, 2024 |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With an expected P/E ratio at 30.33 and 25.84 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -11.82% | 530M | D+ | ||
| +73.17% | 12.38B | B- | ||
| -18.74% | 7.92B | C+ | ||
| +16.15% | 7.2B | C- | ||
| +4.81% | 5.84B | B | ||
| +5.99% | 5.07B | D+ | ||
| +27.07% | 4.53B | - | ||
| -21.67% | 3.88B | B- | ||
| -40.82% | 2.23B | C | ||
| +1.49% | 2.02B | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- IRMD Stock
- Ratings IRADIMED CORPORATION
